UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000063429 |
|---|---|
| Receipt number | R000072599 |
| Scientific Title | Physicians' Disease Awareness and Clinical Practice Patterns in Adult Attention-Deficit/Hyperactivity Disorder Care in Japan: A Descriptive Cross-Sectional Web-Based Survey |
| Date of disclosure of the study information | 2026/10/27 |
| Last modified on | 2026/10/27 16:29:00 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Physicians' Disease Awareness and Clinical Practice Patterns in Adult Attention-Deficit/Hyperactivity Disorder Care in Japan: A Descriptive Cross-Sectional Web-Based Survey
Acronym
Physicians' Disease Awareness and Clinical Practice Patterns in Adult Attention-Deficit/Hyperactivity Disorder Care in Japan: A Descriptive Cross-Sectional Web-Based Survey
Scientific Title
Physicians' Disease Awareness and Clinical Practice Patterns in Adult Attention-Deficit/Hyperactivity Disorder Care in Japan: A Descriptive Cross-Sectional Web-Based Survey
Scientific Title:Acronym
Physicians' Disease Awareness and Clinical Practice Patterns in Adult Attention-Deficit/Hyperactivity Disorder Care in Japan: A Descriptive Cross-Sectional Web-Based Survey
Region
| Japan |
Condition
Condition
Attention-Deficit/Hyperactivity Disorder
Classification by specialty
| Psychiatry |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To describe the clinical practice regarding adult ADHD in Japan, based on data from physicians involved in the care of patients who received an initial ADHD diagnosis during adulthood (age 18 or older).
Basic objectives2
Others
Basic objectives -Others
To identify associations between clinical practices for adults with ADHD and physician characteristics and attributes in Japan.
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Board certifications held,Experience as an occupational physician,Sex,Age,Physician Attributes,Specialty, location of practice,Number of beds in the affiliated institution,Type of institution ,ownership/management,Years of experience in psychiatric practice,Years of experience in ADHD care,Total number of patients managed,Number of adult ADHD patients managed ,Number of newly diagnosed adult ADHD patients,Number of adult ADHD patients prescribed ADHD medications,
Physicians' Diagnostic Style for Adult ADHD,Triggers for suspecting adult ADHD,Sources of information,Methods of accessing information,Diagnostic assessments,Healthcare professionals available to support diagnostic assessments,Reasons for not conducting diagnostic assessments,Approach to diagnosing,Rating scales and assessment tools referenced for diagnosing,Diseases prioritized in the differential diagnosis
Prescribing approach for adult ADHD medications,Actual prescribing practices for adult ADHD medications,Proportion of adult ADHD patients receiving each treatment modality,Reasons for not prescribing adult ADHD medications,Reasons for selecting the most frequently prescribed ADHD medications,Qualification to prescribe Concerta,Treatment goals for adult ADHD patients,Use of concomitant medications used for adult ADHD symptom management
Perceived impact of adult ADHD symptoms on quality of life
Perceived effectiveness of pharmacotherapy
Comorbid diseases that make ADHD symptom control difficult
Concerns regarding adverse effects
Expected benefits of ADHD medications
Level of confidence in diagnosing and treating ADHD
Sources of knowledge
Challenges in diagnosing,non-pharmacological treatment,pharmacological treatment,collaboration among stakeholders involved in ADHD care,clinical practice
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Have managed at least one patient diagnosed with ADHD during adulthood within the previous 6 months.
Hold certification as a board-certified psychiatrist, designated psychiatrist for mental health, or board-certified pediatrician
Be engaged in clinical practice for at least 3 days per week, irrespective of full-time or part-time employment status.
Key exclusion criteria
NA
Target sample size
300
Research contact person
Name of lead principal investigator
| 1st name | Keisuke |
| Middle name | |
| Last name | Onuki |
Organization
Otsuka Pharmaceutical Co., Ltd.
Division name
Medical Affairs Department
Zip code
108-8284
Address
Shinagawa Grand Central Tower 2-16-4 Konan, Minato-ku, Tokyo
TEL
03-6717-1400
Onuki.Keisuke@otsuka.jp
Public contact
Name of contact person
| 1st name | "" |
| Middle name | |
| Last name | "" |
Organization
CareNet, Inc.
Division name
""
Zip code
102-0071
Address
Sumitomo Fudosan Chiyoda Fujimi Building 1-8-19 Fujimi, Chiyoda-ku, Tokyo, Japan
TEL
123
Homepage URL
school@carenet.co.jp
Sponsor or person
Institute
Otsuka Pharmaceutical Co., Ltd.
Institute
Department
Personal name
Funding Source
Organization
Otsuka Pharmaceutical Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
RIHDS Ethics Review Committe
Address
12F, Sumitomo Shibadaimon Building, 2-5-5 Shibadaimon, Minato-ku, Tokyo, Japan
Tel
03-5733-5010
""
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 10 | Month | 27 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2026 | Year | 10 | Month | 20 | Day |
Date of IRB
Anticipated trial start date
| 2026 | Year | 10 | Month | 29 | Day |
Last follow-up date
| 2026 | Year | 11 | Month | 05 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
This study was a cross-sectional study conducted using a web-based questionnaire survey. The planned sample size was 300 participants.
Management information
Registered date
| 2026 | Year | 10 | Month | 27 | Day |
Last modified on
| 2026 | Year | 10 | Month | 27 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072599
